Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Anticancer Res. 2016 Feb;36(2):643–651.

Figure 2.

Figure 2

Cytotoxic effects of the four main theaflavin derivatives on ovarian cancer cells and normal ovarian cells compared according to cell type (A) and theaflavin derivative (B). C: The estimated half-maximal inhibitory concentration (IC50) of the four main theaflavin derivatives against ovarian cancer cells and normal ovarian cells. *p<0.05 compared to the control group.